About Contact Us Careers
Sign In

Myositis Treatment Market Size & Share, by Type (Dermatomyositis, Inclusion-Body Myositis, Juvenile Myositis, Polymyositis, Toxic Myositis); Treatment (Corticosteroids, Immunosuppressant Drug, Physical Therapy); End-user (Hospital, Homecare, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3783
  • Published Date: Mar 20, 2023
  • Report Format: PDF, PPT

Companies Dominating the Myositis Treatment Landscape

top-features-companies
    • Baxter International, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • Novartis AG
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Siemens Healthcare GmbH
    • Pfizer Inc.
    • Becton, Dickinson and Company
    • IBSRELA
    • Indegene
Browse Key Market Insights with Data Illustration:

In the News

  • IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.

  • Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3783
  • Published Date: Mar 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing geriatric population and increasing cases of myositis amongst the older population are estimated to boost the market growth.

The market is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.

The complicated and difficult diagnosis of myositis coupled with the high cost of the treatment and requirement of initial higher investment is estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Baxter International, Inc., Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., Becton, Dickinson and Company, IBSRELA, Indegene and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, treatment, end-user, and by region.

The inclusion-body myositis segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying